Home » J&J Says Boehringer Doxil Dispute May Cause Shortage
J&J Says Boehringer Doxil Dispute May Cause Shortage
Johnson & Johnson says a dispute with Boehringer Ingelheim over an agreement to produce Doxil may actually produce a shortage of that very drug.
Bloomberg
Bloomberg
Upcoming Events
-
07May
-
14May
-
30May